Interleukin-1 blockade in recently decompensated systolic heart failure: study design of the recently decompensated heart failure anakinra response trial (RED-HART) [PDF]
, 2015 Heart Failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to impaired cardiac function. The incidence of HF is increasing and represents the leading cause of hospitalization in the United States among ...
Abbate Antonio +8 more
core +1 more source
Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) [PDF]
, 2017 Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of con-firmed HF cases in the United States. However, there are no highly effective evidence-basedtreatments currently available for these patients.
Abbate, Antonio +10 more
core +1 more source
Anakinra Therapy for Non-cancer Inflammatory Diseases
Frontiers in Pharmacology, 2018 Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-
Giulio Cavalli +3 more
doaj +1 more source
Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
Global & Regional Health Technology Assessment, 2020 Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and ...
Roberto Ravasio +2 more
doaj +1 more source
Severe osteoarticular involvement in isotretinoin-triggered acne fulminans: two cases successfully treated with anakinra. [PDF]
, 2017 Acne fulminans (AF) is a severe form of inflammatory and ulcerated acne associated with fever, malaise, joint swellings and polyarthralgia.1 Osteoarticular lesions are often described and can be radiologically indistinguishable from those observed in
Barbareschi +9 more
core +1 more source
Anakinra reduces lung inflammation in experimental acute lung injury
Immunity, Inflammation and Disease, 2022 Introduction Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury (ALI) resulting in life‐threatening hypoxaemia. Although ARDS can be caused by a variety of pathogens or major trauma, it is best known as the major cause of ...
Paul Engeroff +3 more
doaj +1 more source
Macrophage TNF-α mediates parathion-induced airway hyperreactivity in guinea pigs. [PDF]
, 2013 Organophosphorus pesticides (OPs) are implicated in human asthma. We previously demonstrated that, at concentrations that do not inhibit acetylcholinesterase activity, the OP parathion causes airway hyperreactivity in guinea pigs as a result of ...
Allison D. Fryer +12 more
core +1 more source
Muckle-Wells treatment with anakinra [PDF]
Dermatology Online Journal, 2013 A 35-year-old man initially was referred for management of recalcitrant urticaria. Owing to his long history of arthritis and sensorineural hearing loss, genetic testing was performed. The test showed a D305N heterozygous mutation in the NLRP3 gene, which is consistent with the diagnosis of Muckle-Wells syndrome.
Eungdamrong, John +3 more
openaire +5 more sources
Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease [PDF]
, 2018 Adult-onset Still's disease (AOSD) is a rare inflammatory disease of unknown etiology typically characterized by episodes of spiking fever, evanescent rash, arthralgia, leukocytosis, and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other
Baggio, Chiara +4 more
core +1 more source
Anakinra in children and adults with Still’s disease [PDF]
Rheumatology, 2019 AbstractSystemic juvenile idiopathic arthritis and adult-onset Still’s disease are rare autoinflammatory disorders with common features, supporting the recognition of these being one disease—Still’s disease—with different ages of onset. Anakinra was recently approved by the European Medicines Agency for Still’s disease.
Vastert, Sebastiaan +8 more
openaire +5 more sources